AstraZeneca raises 2022 guidance, names Demaré as non-exec chair
AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – […]
AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – […]
Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year […]
Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks, but is already off to a […]
In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning […]
Teva Pharmaceutical says it has reached an agreement in principle to settle thousands of lawsuits accusing it of fuelling the opioid crisis in the US […]
Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for […]
Novartis said this morning that it remains on course to make a decision on the future of its generics business Sandoz by the end of […]
GSK’s consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a […]
A report by the Senate Finance Committee has concluded that AbbVie exploited a financial loophole introduced by former President Donald Trump in 2017 to avoid […]
GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new […]
Biogen has announced a major revamp of its business that will see chief executive Michel Vounatsos depart the company, and all commercial activities related to […]
AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven […]
Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by a massive 50%, although underlying growth was […]
Hospitals needs to make changes not only to retain clinicians but to stem financial losses. Healthcare leaders are committed to rising to the challenge, and […]
Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests […]
Gene therapy specialist bluebird bio has said 30% of its workforce will lose their jobs, in a bid to conserve cash as it tried to […]
Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over full responsibility to its US […]
As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises “substantial doubt” about its ability […]
Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, […]
AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, […]
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), […]
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its […]
Roche has warned that revenue growth will come under pressure in the coming year as sales of its COVID-19 testing kits start to slow, exposing […]
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on […]
Johnson & Johnson has said the impending spin-off of its consumer health division won’t stop it from “forging ahead” with M&A deals to expand its […]
AstraZeneca has said it plans to start making a small profit from sales of its COVID-19 vaccine Vaxzevria, which brought in just over $1 billion […]
Under fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have reached an agreement that could see the […]
After more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma group Roche for $20.7 billion, a decent […]
Rocketing sales of COVID-19 vaccine Comirnaty have allowed Pfizer to raise its full-year forecasts for the shot once again to a whopping $36 billion, more […]
President Joe Biden has jettisoned a raft of policy proposals aimed at curbing the price of prescription medicines as part of the US administration’s $1.75 […]
GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on […]
Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to […]
Activist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the […]
Analysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug […]
High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche’s diagnostics division, allowing the company to raise its […]
Johnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became available, but is thinking about a possible […]
AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but […]
The UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a broader inquiry into the deal. The nod […]
Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world’s biggest-selling […]
Getting sick creates risk over two dimensions. First, you risk getting sick which of course decreases your utility. Second, getting sick impacts you financially as […]
Cedar, a healthcare finance technology company, saw its valuation jump to $3.2 billion after raising $200 million in a Series D funding round. It plans […]
DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a […]
Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment with its Veklury antiviral, and its latest […]
Copyright © 2024 | WordPress Theme by MH Themes